Akari Therapeutics (NASDAQ:AKTX) Stock Price Passes Above 50 Day Moving Average – Should You Sell?

Akari Therapeutics PLC (NASDAQ:AKTX) crossed above its fifty day moving average during trading on Tuesday . The stock has a fifty day moving average of $9.45 and traded as high as $12.21. Akari Therapeutics shares last traded at $11.79, with a volume of 60,271 shares.

Analyst Ratings Changes

A number of equities analysts have issued reports on AKTX shares. Weiss Ratings restated a “sell (e+)” rating on shares of Akari Therapeutics in a report on Monday, April 20th. Maxim Group lowered shares of Akari Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, April 8th. Finally, HC Wainwright boosted their target price on shares of Akari Therapeutics to $27.00 and gave the company a “buy” rating in a research report on Wednesday, April 1st. Two equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Akari Therapeutics has an average rating of “Hold” and an average price target of $89.00.

Akari Therapeutics Price Performance

The business has a 50-day moving average of $9.68 and a 200 day moving average of $9.47.

Akari Therapeutics (NASDAQ:AKTX) last announced its quarterly earnings results on Wednesday, May 20th. The biopharmaceutical company reported ($688.00) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.33) by ($686.67).

Institutional Trading of Akari Therapeutics

A hedge fund recently raised its stake in Akari Therapeutics stock. Cresset Asset Management LLC raised its holdings in shares of Akari Therapeutics PLC (NASDAQ:AKTX) by 4,368.0% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 822,468 shares of the biopharmaceutical company’s stock after purchasing an additional 804,060 shares during the quarter. Cresset Asset Management LLC owned 2.52% of Akari Therapeutics worth $831,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 5.06% of the company’s stock.

About Akari Therapeutics

Akari Therapeutics plc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel complement inhibitors for the treatment of inflammatory and immunological diseases. The company’s research centers on modulation of the complement cascade, a key component of the innate immune system, with the goal of delivering targeted therapies to patients suffering from rare and severe disorders.

Akari’s lead pipeline asset is sutimlimab, a humanized monoclonal antibody that selectively inhibits the C1s protein and is being evaluated in pivotal clinical studies for cold agglutinin disease.